Adenocarcinoma of the gastroesophageal junction
Information
- Disease name
- Adenocarcinoma of the gastroesophageal junction
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01939275 | Active, not recruiting | N/A | 64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer | November 19, 2014 | December 30, 2024 |
| NCT02037048 | Active, not recruiting | Phase 2 | FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma | February 10, 2014 | October 1, 2025 |
| NCT04681248 | Available | Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors | |||
| NCT00084617 | Completed | Phase 2 | Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma | March 2004 | December 2008 |
| NCT00253370 | Completed | Phase 2 | Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer | October 2005 | September 2010 |
| NCT00607594 | Completed | Phase 2 | Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer | January 2008 | April 2012 |
| NCT00757172 | Completed | Phase 2 | Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction | January 2009 | December 2014 |
| NCT00891878 | Completed | Phase 2 | Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction | August 2009 | January 2013 |
| NCT00938470 | Completed | Phase 2 | Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction | January 2010 | March 2018 |
| NCT00978549 | Completed | Phase 3 | Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer | April 2008 | October 2010 |
| NCT00982592 | Completed | Phase 2 | Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer | September 2009 | October 2014 |
| NCT00991952 | Completed | Phase 2 | Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery | September 2009 | April 2014 |
| NCT01107639 | Completed | Phase 3 | Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery | May 27, 2010 | December 9, 2018 |
| NCT02013154 | Completed | Phase 1 | A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab | May 5, 2014 | January 11, 2021 |
| NCT00061932 | Completed | Phase 2 | Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach | April 2003 | November 2013 |
| NCT00084604 | Completed | Phase 2 | Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | April 2004 | |
| NCT01260701 | Completed | Phase 2 | Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer | January 2011 | July 2015 |
| NCT01333033 | Completed | Phase 2 | PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy | July 2011 | April 1, 2023 |
| NCT01360086 | Completed | Phase 2 | Fluorouracil, Cisplatin, Leucovorin Calcium, and Cetuximab in Treating Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction | June 2011 | March 2013 |
| NCT01472029 | Completed | Phase 2 | Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach | December 2011 | September 12, 2016 |
| NCT01498289 | Completed | Phase 2 | S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer | February 2012 | September 19, 2019 |
| NCT01561014 | Completed | Phase 1 | Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction | April 2007 | March 2009 |
| NCT01582906 | Completed | A Survivorship Care Plan for Gynaecological Cancer Patients | August 2011 | April 2015 | |
| NCT01612546 | Completed | Phase 2 | Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery | November 2012 | January 15, 2015 |
| NCT01640782 | Completed | Phase 3 | Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach | February 2005 | January 2013 |
| NCT01851928 | Completed | Validation of a Nutrition Screening Tool | July 2011 | March 2013 | |
| NCT01855854 | Completed | Phase 2 | Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH | May 2013 | January 7, 2016 |
| NCT00045526 | Completed | Phase 2 | Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer | June 2002 | |
| NCT02443324 | Completed | Phase 1 | A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer | July 29, 2015 | April 12, 2022 |
| NCT02680990 | Completed | N/A | Resilience and Exercise in Advanced Cancer Treatment | December 2015 | July 2017 |
| NCT02918162 | Completed | Phase 2 | Perioperative Chemo and Pembrolizumab in Gastric Cancer | November 25, 2017 | February 28, 2023 |
| NCT01178944 | Completed | Phase 2 | Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer | September 2010 | November 2015 |
| NCT01183559 | Completed | Phase 1 | A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery | August 7, 2008 | August 2011 |
| NCT01212822 | Completed | Phase 2 | Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer | April 27, 2011 | January 3, 2018 |
| NCT01216813 | Completed | Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological Cancer | August 2010 | December 2010 | |
| NCT01231399 | Completed | Phase 1/Phase 2 | Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer | February 2012 | July 2016 |
| NCT01243398 | Completed | Phase 3 | Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy | March 2009 | May 2012 |
| NCT04028167 | Recruiting | Phase 2 | Induction FLOT With CROSS CRT for Esophageal Cancer | April 8, 2020 | April 2026 |
| NCT01395537 | Terminated | Phase 1/Phase 2 | Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ) | August 2011 | December 2014 |
| NCT00732745 | Terminated | Phase 1 | Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction | October 2008 | |
| NCT02485834 | Terminated | Phase 2 | FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer | August 2015 | August 2018 |
| NCT00064259 | Terminated | Phase 1/Phase 2 | A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer | June 2003 | February 2010 |
| NCT03722108 | Terminated | Phase 1/Phase 2 | Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas | February 7, 2019 | May 19, 2022 |
| NCT01123473 | Terminated | Phase 2 | Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer | December 2010 | September 2014 |
| NCT02234180 | Terminated | Phase 2 | Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery | September 2014 | June 8, 2016 |
| NCT01307956 | Terminated | Phase 2 | Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer | February 28, 2011 | December 23, 2015 |
| NCT01705340 | Terminated | Phase 1 | Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery | September 2012 | |
| NCT01523015 | Unknown status | Phase 2/Phase 3 | Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction | January 2012 | December 2020 |
| NCT04773769 | Unknown status | N/A | Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas | November 7, 2018 | November 2023 |
| NCT00963092 | Unknown status | Study of Blood and Tissue Samples From Patients With Stomach Cancer, Esophageal Cancer, or Gastroesophageal Junction Cancer | August 2002 | ||
| NCT03307941 | Withdrawn | Phase 1/Phase 2 | Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA | July 20, 2017 | December 11, 2017 |
| NCT02344810 | Withdrawn | Phase 1/Phase 2 | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer | March 6, 2015 |